/
We are a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration ( FDA ) approved prescription pharmaceutical products for the treatment of dermatological conditions.
The business is unprofitable at the operating level (-13.21% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 10.2% YoY with margins expanding 11.2pp.
Insufficient data to identify specific risks. Treat any missing metrics as a data gap, not a clean bill of health.
Profitability & Returns
Revenue (TTM)
$65M
▲ +10.2% YoY
Net Income (TTM)
-$10M
▲ +22.1% YoY
Op. Margin
-9.80%
▲ +11.2pp YoY
ROIC
-9.57%
▲ +14.3pp YoY
Cash Flow & Balance Sheet
FCF
N/A
Op. Cash Flow (TTM)
-$7M
▼ -36.3% YoY
Net Debt
-$2M
Net Cash Position
Cash & Equiv.
$27M
5Y CAGR: +6.8%
Continue Research